Constipation - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 122 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Constipation - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Constipation - Pipeline Review, H1 2016', provides an overview of the Constipation pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Constipation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Constipation and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Constipation
- The report reviews pipeline therapeutics for Constipation by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Constipation therapeutics and enlists all their major and minor projects
- The report assesses Constipation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Constipation

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Constipation
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Constipation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Constipation Overview 9
Therapeutics Development 10
Pipeline Products for Constipation - Overview 10
Pipeline Products for Constipation - Comparative Analysis 11
Constipation - Therapeutics under Development by Companies 12
Constipation - Therapeutics under Investigation by Universities/Institutes 14
Constipation - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Constipation - Products under Development by Companies 18
Constipation - Products under Investigation by Universities/Institutes 20
Constipation - Companies Involved in Therapeutics Development 21
AlbireoPharma 21
Ardelyx, Inc. 22
Astellas Pharma Inc. 23
Braintree Laboratories, Inc. 24
CJ HealthCare Corp. 25
Daiichi Sankyo Company, Limited 26
Ironwood Pharmaceuticals, Inc. 27
Kissei Pharmaceutical Co., Ltd. 28
NGM Biopharmaceuticals, Inc. 29
RaQualia Pharma Inc. 30
Rhythm Pharmaceuticals, Inc. 31
Sanwa Kagaku Kenkyusho Co., Ltd. 32
Shire Plc 33
SK Biopharmaceuticals Co., Ltd. 34
Sucampo Pharmaceuticals, Inc. 35
Sumitomo Dainippon Pharma Co., Ltd. 36
Synergy Pharmaceuticals, Inc. 37
Synthetic Biologics, Inc. 38
Yuhan Corporation 39
Constipation - Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Target 41
Assessment by Mechanism of Action 43
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
ASP-7663 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
BLI-400 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
DA-6886 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
DS-3801 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
DSP-6952 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
elobixibat - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
KWA-0711 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
linaclotide - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
lubiprostone - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
NGM-282 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
plecanatide - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
prucalopride succinate - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
relamorelin - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
relenopride hydrochloride - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
RQ-00000010 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
SK-1202 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecule to Activate 5-HT1 Receptor for Constipation and Dyspepsia - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Small Molecule to Inhibit IBAT for Chronic Constipation and Irritable Bowel Syndrome - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
SYN-010 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
tenapanor hydrochloride - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Transilon - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
YH-12852 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Constipation - Recent Pipeline Updates 82
Constipation - Dormant Projects 111
Constipation - Product Development Milestones 112
Featured News & Press Releases 112
Jan 29, 2016: Synergy Pharmaceuticals Files New Drug Application for Plecanatide in Chronic Idiopathic Constipation 112
Jan 19, 2016: Synthetic Biologics Reports Positive Topline Data from Second Phase 2 Clinical Trial of SYN-010 in Patients with Irritable Bowel Syndrome with Constipation (IBS-C) 113
Dec 08, 2015: Synthetic Biologics' SYN-010 Lowered Breath Methane and Improved Stool Frequency in a Phase 2 Four Week Study in Patients with Irritable Bowel Syndrome with Constipation (IBS-C) 114
Dec 07, 2015: Synthetic Biologics to Webcast Microbiome Clinical Program Seminar 115
Nov 30, 2015: Astellas and Ironwood Report Positive Top-Line Data from Phase III IBS-C Trial Conducted in Japan 116
Nov 24, 2015: Synthetic Biologics Announces Issuance of First Key U.S. Patent Directly Covering SYN-010, the Company's Novel Candidate for Irritable Bowel Syndrome with Constipation 117
Nov 19, 2015: Synthetic Biologics to Host Microbiome Clinical Program Seminar in New York City 117
Nov 10, 2015: Albireo Announces the Initiation in Japan of a Phase 3 Clinical Trial of Elobixibat in Chronic Constipation by Ajinomoto Pharmaceuticals 118
Nov 02, 2015: Ironwood and Allergan Initiate Phase IIb Clinical Trial of Linaclotide Colonic Release in Adults with Irritable Bowel Syndrome with Constipation 118
Oct 20, 2015: Synthetic Biologics' Novel Irritable Bowel Syndrome with Constipation Program Featured in American College of Gastroenterology Poster 119
Appendix 121
Methodology 121
Coverage 121
Secondary Research 121
Primary Research 121
Expert Panel Validation 121
Contact Us 121
Disclaimer 122

List of Tables
Number of Products under Development for Constipation, H1 2016 10
Number of Products under Development for Constipation - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Comparative Analysis by Late Stage Development, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Development, H1 2016 17
Products under Development by Companies, H1 2016 18
Products under Development by Companies, H1 2016 (Contd..1) 19
Products under Investigation by Universities/Institutes, H1 2016 20
Constipation - Pipeline by AlbireoPharma, H1 2016 21
Constipation - Pipeline by Ardelyx, Inc., H1 2016 22
Constipation - Pipeline by Astellas Pharma Inc., H1 2016 23
Constipation - Pipeline by Braintree Laboratories, Inc., H1 2016 24
Constipation - Pipeline by CJ HealthCare Corp., H1 2016 25
Constipation - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 26
Constipation - Pipeline by Ironwood Pharmaceuticals, Inc., H1 2016 27
Constipation - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016 28
Constipation - Pipeline by NGM Biopharmaceuticals, Inc., H1 2016 29
Constipation - Pipeline by RaQualia Pharma Inc., H1 2016 30
Constipation - Pipeline by Rhythm Pharmaceuticals, Inc., H1 2016 31
Constipation - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H1 2016 32
Constipation - Pipeline by Shire Plc, H1 2016 33
Constipation - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 34
Constipation - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 35
Constipation - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 36
Constipation - Pipeline by Synergy Pharmaceuticals, Inc., H1 2016 37
Constipation - Pipeline by Synthetic Biologics, Inc., H1 2016 38
Constipation - Pipeline by Yuhan Corporation, H1 2016 39
Assessment by Monotherapy Products, H1 2016 40
Number of Products by Stage and Target, H1 2016 42
Number of Products by Stage and Mechanism of Action, H1 2016 44
Number of Products by Stage and Route of Administration, H1 2016 46
Number of Products by Stage and Molecule Type, H1 2016 48
Constipation Therapeutics - Recent Pipeline Updates, H1 2016 82
Constipation - Dormant Projects, H1 2016 111